Learn About Tests Used for Triple Negative Breast Cancer

Triple negative breast cancer is diagnosed and evaluated through several tests that help identify the characteristics, location, and extent of the disease. A biopsy is used to confirm whether breast cells are cancerous, while receptor testing determines whether estrogen receptors, progesterone receptors, and HER2 proteins are present. Imaging tests may help assess the breast and nearby areas. Additional genetic and biomarker tests can provide information about inherited gene changes and specific tumor features. Together, these tests support accurate diagnosis, staging, and treatment planning based on the individual characteristics of the cancer.

Triple negative breast cancer is a type of breast cancer in which the cancer cells do not have estrogen receptors, progesterone receptors, or high levels of HER2 protein. Because these three commonly tested markers are absent, laboratory and diagnostic testing plays an important role in confirming the diagnosis and understanding the characteristics of the cancer. Healthcare professionals may use tissue testing, imaging, blood-related assessments, and genetic or biomarker analysis to gather information that supports diagnosis and treatment planning.

Biopsy and Receptor Tests for Diagnosis

A biopsy is one of the main tests used to diagnose breast cancer. During this procedure, a sample of suspicious breast tissue or cells is collected and examined in a laboratory. The examination can determine whether cancer is present and identify characteristics of the tumor.

Receptor testing is performed on the cancer tissue to determine whether the cells contain hormone receptors or HER2 proteins. Triple negative breast cancer is identified when estrogen receptor, progesterone receptor, and HER2 testing do not show the features required for hormone-targeted or HER2-targeted classification.

Common diagnostic tests may include:

• Core needle biopsy: A hollow needle is used to collect tissue samples from an abnormal area.
• Fine needle aspiration: A thin needle may be used to collect cells or fluid from a suspicious area.
• Estrogen receptor testing: This checks whether cancer cells contain estrogen receptors.
• Progesterone receptor testing: This determines whether progesterone receptors are present.
• HER2 testing: This evaluates the amount or activity of the HER2 protein or related gene changes.
• Pathology examination: A pathologist studies the tissue to identify cancer type, grade, and other cellular characteristics.

These tests help distinguish triple negative breast cancer from other breast cancer subtypes and provide information about the biological features of the tumor.

Imaging and Additional Tests for Cancer Assessment

After breast cancer is identified, additional tests may be used to understand the size and location of the tumor and determine whether cancer has affected nearby lymph nodes or other parts of the body. The type of testing used can depend on the individual's symptoms, tumor characteristics, and clinical findings.

Imaging tests can provide detailed pictures of breast tissue and other areas of the body. Some imaging procedures may be used during the initial evaluation, while others may be considered when additional information is needed for staging.

Tests that may be used include:

• Mammography: Uses low-dose X-rays to identify abnormalities within breast tissue.
• Breast ultrasound: Uses sound waves to create images and may help evaluate a lump or abnormal area.
• Breast MRI: Produces detailed images and may provide additional information about the extent of disease.
• CT scan: May be used to examine specific areas of the body when clinically appropriate.
• PET scan: Can help identify areas with increased metabolic activity in certain situations.
• Bone scan: May be considered when there is a clinical reason to assess possible bone involvement.
• Genetic testing: May identify inherited changes in genes such as BRCA1 or BRCA2, which can be relevant for some people with triple negative breast cancer.
• Biomarker testing: May examine specific features of the tumor that could provide additional information for treatment planning.

The combination of pathology, receptor testing, imaging, and other appropriate laboratory assessments provides a detailed picture of triple negative breast cancer. Test results can help healthcare professionals confirm the cancer subtype, determine its stage, evaluate tumor characteristics, and discuss suitable management approaches. The specific tests used may vary according to individual clinical circumstances and the information already available from earlier examinations.